Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Managed Care November 2004 Thomas Morrow	Pharmacogenetic, Pharmacogenomic Testing Rapidly Gaining Acceptance New tests will allow better determination of which therapies will work on which patients, thus improving care and reducing outlays for failed therapies.
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
Bio-IT World October 10, 2003 Kevin Davies	Iressa's Trials and Tribulations The Iressa experience highlights the enormous stakes surrounding breakthrough therapies.
Chemistry World June 12, 2012 Nina Notman	Three pronged approach puts brakes on US breast cancer The US Food and Drug Administration (FDA) has approved the use of anti-HER2 therapy Perjeta (pertuzumab) to treat patients with previously untreated HER2-positive metastatic breast cancer.
HHMI Bulletin Nov 2010	Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers.
Chemistry World July 3, 2015 Andy Extance	Pharma queues up for checkpoint inhibitor collaborations Amid fierce rivalries over the latest generation of cancer treatments, drug makers have been weaving a complex web of collaborations on combination therapies spanning much of the pharmaceutical industry.
The Motley Fool December 20, 2004 Charly Travers	More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
The Motley Fool November 19, 2004 Charly Travers	A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer.
Scientific American March 2009 Elaine Schattner	A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment
Bio-IT World August 13, 2002 Kevin Davies	Curtailing the Cancerous Cell The highly touted drug Gleevec unleashed new hope in the battle against cancer. Now a group of new drugs, working on the same principle, are showing even greater promise in treating leukemia.
Chemistry World July 21, 2011 Elinor Richards	Cell Control to Change Cell Function US scientists can now control the reactions occurring inside cells.
Bio-IT World August 13, 2003 Malorye Branca	Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm.
The Motley Fool May 22, 2008 Brian Lawler	All Is Not Lost for AstraZeneca's Iressa AstraZeneca's Iressa gets a little pep back.
Chemistry World June 12, 2014 Andy Extance	Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Non-Small-Cell Lung Cancer: Targeting Pathways and Patients Although the most common cancer worldwide, lung cancer remains poorly treated, with the highest mortality rate.
Chemistry World February 23, 2009 Nina Notman	Resistant breast cancers re-sensitised to Tamoxifen A way to re-sensitise certain drug-resistant breast cancers to treatments such as Tamoxifen could offer better treatment for people with hard-to-beat cancers.
Chemistry World September 2010	Column: In the pipeline Derek Lowe considers the quandaries of living in the age of the kinase
Chemistry World July 2010 Hayley Birch	Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade.
Wired August 2003 Jennifer Kahn	The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine.
Pharmaceutical Executive November 1, 2013 Ben Comer	2014 Pipeline Report: The Sprint to Value Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters.
Registered Rep. February 1, 2005 Bob Hirschfeld	Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street.
Pharmaceutical Executive November 1, 2014 Josh Baxt	2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
Bio-IT World June 17, 2004	Minority Report With Iressa, the AstraZeneca drug approved by the FDA last year, there is a small group, maybe 10 to 20 percent of lung cancer patients, who get an almost miraculous response. Mutations may explain patient responses to the drug.
BusinessWeek May 27, 2010 Pettypiece & Gibson	Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer."
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
HHMI Bulletin Nov 2011 Renee Twombly	A New Take on Retinoblastoma Basic research findings upend old thoughts on this childhood tumor.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument.
BusinessWeek March 8, 2004 Arlene Weintraub	And When ImClone's Drug Doesn't Work... Physicians have greeted ImClone Systems Inc.'s (IMCL ) cancer drug, Erbitux, with a mixture of glee and grim realism. The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect -- and no one knows why.
The Motley Fool July 16, 2007 Brian Lawler	Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note.
The Motley Fool May 8, 2009 Brian Orelli	Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector?
Chemistry World December 9, 2013 James Urquhart	Drug fix for misfolded proteins promises hope for incurable diseases Researchers have been looking into pharmacological chaperones or pharmacoperones. They might treat diseases brought about by genetic mutations that cause otherwise functional proteins to become misfolded or misrouted.
The Motley Fool January 5, 2005 Charly Travers	AstraZeneca's Lead Evaporates Pulling an application for Iressa from the EU makes the drug a has-been.
Pharmaceutical Executive February 1, 2013 William Looney	Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice.
Chemistry World October 14, 2008 Simon Hadlington	Enzymes hit with double punch US chemists have made a small molecule that simultaneously blocks two key enzymes involved in the growth of cancer cells.
The Motley Fool November 2, 2004 Charly Travers	Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer.
Chemistry World October 7, 2012 David Bradley	Magnetic nanoparticles zap cancer Nanoparticles can be used as a remote-controlled magnetic death switch to kill cancer cells, according to researchers from Korea.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
The Motley Fool September 13, 2007 Brian Lawler	ImClone Expanding on Erbitux ImClone's turnaround continues with positive results in a cancer study with their lead drug Erbitux.
BusinessWeek September 5, 2005 Michael Arndt	Fine-Tuning the Attack on Breast Cancer Genentech's Herceptin, the first drug approved for a specific group, helps patients who are genetically susceptible to a virulent form of the disease.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
Pharmaceutical Executive March 1, 2013 Keeling & Paz	Early Engagement with Medical Laboratories Timely engagement is the key to expanding the use of companion diagnostics.
Chemistry World July 2010	Column: In the pipeline Derek Lowe ponders the possibility of phosphatase inhibitors
The Motley Fool June 4, 2008 Brian Lawler	Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares.
Pharmaceutical Executive December 1, 2008 Ron Feemster	The 2008 Pipeline Report We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
BusinessWeek June 21, 2004 Catherine Arnst	Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs.
Chemistry World December 3, 2007 Lewis Brindley	Cancer Drug Gets a Makeover Scientists in the US have used a new drug design strategy to remove the cardiac side-effects of a popular cancer drug. The approach could help make other cancer treatments safer, researchers say.